OFIX logo

ORTHOFIX MEDICAL INC

OFIXNASDAQ
πŸ† #2765 by market capEarnings Nov 3US Equity
$10.18β–Ό $0.14 (βˆ’1.36%)
Live
1hβ€”
24hβ–Ό 1.4%
7dβ–Ό 1.9%
14dβ–Ό 16.4%
30dβ–Ό 13.7%
1yβ–Ό 26.3%
🏦Market Cap
$411M
Small Cap
πŸ“ˆRevenue Growth (YoY)
+2.6%
Slowing
πŸ“ŠGross Margin
70.8%
High
πŸ’΅FCF Margin
2.9%
Thin
βš–οΈP/S Ratio
0.5x
Cheap
Otter Score
55
Weak

Trading Snapshot

Day Range
$10.11 – $10.35
52-Week Range
$8.85 – $16.99
Volume
$2.02B
Avg Volume
$2.55B
Shares Outstanding
40.4M
Next Earnings
Oct 4, 2026

Fundamentals Snapshot

Annual Revenue
$822M
Last Q Revenue
$211M
P/E Ratio
β€”
P/S Ratio
0.5x
EPS (TTM)
$-1.50
Dividend Yield
β€”

Why Investors Own OFIX

  • βœ“High-growth profile β€” revenue up +1.2% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 61% gross margin and 14% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)
$822Mβ–Ό βˆ’1.1% YoY
Gross Margin (TTM)
60.7%β–² +3.5% YoY
Operating Income (TTM)
$118Mβ–Ό βˆ’1.1% YoY
Free Cash Flow (TTM)
$115Mβ–Ό βˆ’1.1% YoY

About ORTHOFIX MEDICAL INC

Orthofix Medical Inc., founded in 1980 and headquartered in Lewisville, Texas, operates as a global medical technology company focusing on devices and biologics. Its reach extends across the United States, several European nations including Italy, Germany, France, and the United Kingdom, as well as Brazil and other international markets. The company's operations are divided into two main segments: Global Spine and Global Orthopedics. Within the Global Spine division, Orthofix is responsible for the development, production, and distribution of bone growth stimulators. These devices are designed to facilitate bone fusion and serve as a therapeutic intervention for fractures located outside the spine and in the limbs. This segment also creates and commercializes a range of motion preservation and fixation implant products utilized in spinal surgical procedures. Furthermore, it supplies physicians with various tissue forms and synthetic-based regenerative biologic solutions to address a wide spectrum of spinal and orthopedic conditions. The Global Orthopedics segment concentrates on the design, development, and commercialization of specialized orthopedic products. These offerings are essential for procedures involving fracture repair, the correction of deformities, and bone reconstruction. Orthofix distributes its products to a diverse clientele, including physicians, hospitals, outpatient surgery centers, and integrated health delivery systems. This is achieved through a comprehensive sales network that includes its own sales force, independent distributors, and both employed and external sales representatives. The company, previously known as Orthofix International N.V., officially changed its name to Orthofix Medical Inc. in July 2018.

🦦

Otter Score Breakdown

β“˜
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
Overall Score
Weak
55/100

Analyst Price Target

β“˜
Average Target
$11.32
β–² +11.2% Upside
High Target$13.97
Low Target$10.08
Based on 12 analysts

Latest News & Updates